Long non-coding RNA NCK1-AS1 promotes the tumorigenesis of glioma through sponging microRNA-138-2-3p and activating the TRIM24/Wnt/β-catenin axis

Huang, Lifa; Li, Xu; Ye, Hui; Liu, Yajun; Liang, Xiaolong; Yang, Chao; Hua, Lin; Yan, Zhaoxian; Zhang, Xin

doi:10.1186/s13046-020-01567-1

Cited by 32 publications

(14 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, lncRNA NCK1-AS1 enhances growth and metastasis of glioma through targeting miR-138-2-3p to activate βcatenin signaling. 2 LncRNA CCAT2 contributes to glioma progression by activating VEGFA pathway. 15 LncRNA LINC00467 upregulation promotes glioma development through repressing P53 level.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long Noncoding RNA LINC00173 Promotes NUTF2 Expression Through Sponging miR-765 and Facilitates Tumorigenesis in Glioma

Du¹,

Liu²,

Tian³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Glioma is one of the leading causes of cancer-related deaths. This study aimed to investigate the function and mechanism of long noncoding RNA (lncRNA) LINC00173 in the regulation of glioma progression. Methods: LINC00173 expression was measured using qRT-PCR. Survival rate was analyzed through Kaplan-Meier method. CCK8, colony formation and EdU assays were performed to measure cell proliferation while transwell was used to determine cell migration and invasion. Luciferase reporter assay was conducted to test RNA interaction. Results: LINC00173 expression was elevated in glioma tissues and cells. LINC00173 high expression predicted poor prognosis. Loss of LINC00173 inhibited proliferation, migration and invasion. LINC00173 interacted with miR-765 to enhance NUTF2 expression. MiR-765 expression was negatively correlated with LINC00173 and NUTF2 in glioma tissues. NUTF2 level was increased in glioma tissues. NUTF2 overexpression rescued the potential of proliferation, migration and invasion in LINC00173-silenced cells. Conclusion: Our research demonstrated that LINC00173 promotes glioma progression through targeting miR-765/NUTF2 axis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…1 The current clinically therapeutic strategies are surgery combined with chemotherapy and radiotherapy. 2 However, the prognosis of glioma patients remains not well post therapy. 3 Hence, it is urgently required to discover new molecular mechanism for glioma therapy.…”

Section: Introductionmentioning

confidence: 99%

Long Noncoding RNA LINC00173 Promotes NUTF2 Expression Through Sponging miR-765 and Facilitates Tumorigenesis in Glioma

Du¹,

Liu²,

Tian³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…The siRNA-mediated Bcl-xL downregulation potentiates the inhibitory effect on the malignancy and growth of PCa cells [ 78 ]. Another example of successful siRNA treatment is the tripartite motif-containing protein 24 (TRIM24), a carcinogenesis factor capable of enhancing progression and viability of different cancers [ 79 , 80 ]. The strategy is based on suppressing TRIM24 in cancer therapy [ 81 ].…”

Section: Sirna Targets Signaling Pathways: Focus On Pca Therapymentioning

confidence: 99%

Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

Prostate cancer (PCa) accounts for a high number of deaths in males with no available curative treatments. Patients with PCa are commonly diagnosed in advanced stages due to the lack of symptoms in the early stages. Recently, the research focus was directed toward gene editing in cancer therapy. Small interfering RNA (siRNA) intervention is considered as a powerful tool for gene silencing (knockdown), enabling the suppression of oncogene factors in cancer. This strategy is applied to the treatment of various cancers including PCa. The siRNA can inhibit proliferation and invasion of PCa cells and is able to promote the anti-tumor activity of chemotherapeutic agents. However, the off-target effects of siRNA therapy remarkably reduce its efficacy in PCa therapy. To date, various carriers were designed to improve the delivery of siRNA and, among them, nanoparticles are of importance. Nanoparticles enable the targeted delivery of siRNAs and enhance their potential in the downregulation of target genes of interest. Additionally, nanoparticles can provide a platform for the co-delivery of siRNAs and anti-tumor drugs, resulting in decreased growth and migration of PCa cells. The efficacy, specificity, and delivery of siRNAs are comprehensively discussed in this review to direct further studies toward using siRNAs and their nanoscale-delivery systems in PCa therapy and perhaps other cancer types.

show abstract

“…NCK1-AS1 was found to serve as oncogenic lncRNA in several cancers. 9,10,17 However, the roles and associated mechanisms of NCK1-AS1 in regulating GC remain unclear. In this study, we showed that NCK1-AS1 was upregulated expression in GC tissues and cells, indicating that NCK1-AS1 may play a crucial role in regulating GC progression.…”

Section: Dovepressmentioning

confidence: 99%

Long Non-Coding RNA NCK1-AS1 Serves an Oncogenic Role in Gastric Cancer by Regulating miR-137/NUP43 Axis

Li¹,

Duan²,

Shi³

et al. 2020

OTT

View full text Add to dashboard Cite

Introduction: Long non-coding RNA (lncRNA) NCK1-AS1 could regulate multiple cancer progression. However, little is known regarding the roles and acting mechanisms of NCK-AS1 in gastric cancer (GC) progression. This work was aimed to explore the relationship between NCK1-AS1 and GC progression to illustrate the mechanisms of NCK1-AS1. Methods: NCK1-AS1 expression level in GC tissues and cells was measured with a quantitative real-time PCR method. In vitro experiments including cell counting kit-8 assay, colony formation assay, wound-healing assay, and transwell invasion assay were employed to detect biological roles of NCK1-AS1 in GC progression. In vivo experiments were performed to analyze the roles of NCK1-AS1 on GC malignant phenotype. Moreover, mechanisms behind the biological roles of NCK1-AS1 in GC were investigated using bioinformatic analysis, luciferase activity reporter assay, RNA immunoprecipitation assay, and rescue experiments. Results: NCK1-AS1 was found to have elevated expression in GC tissues and cells in comparison with normal counterparts. Loss-of-function experiments showed knockdown of NCK1-AS1 refrained GC cell proliferation, colony formation, migration, and invasion in vitro. Animal experiments showed silence of NCK1-AS1 suppresses tumor growth in vivo. Functionally, NCK1-AS1 serves as a sponge for microRNA-137 (miR-137) to upregulate nucleoporin 43 (NUP43) expression in GC. Rescue experiments proved the carcinogenic role of NCK1-AS1/miR-137/NUP43 axis in GC progression. Discussion: In conclusion, the NCK1-AS1/miR-137/NUP43 axis was identified that could contribute to GC malignancy behaviors.

show abstract

Long non-coding RNA NCK1-AS1 promotes the tumorigenesis of glioma through sponging microRNA-138-2-3p and activating the TRIM24/Wnt/β-catenin axis

Cited by 32 publications

References 47 publications

<p>Long Noncoding RNA LINC00173 Promotes NUTF2 Expression Through Sponging miR-765 and Facilitates Tumorigenesis in Glioma</p>

<p>Long Noncoding RNA LINC00173 Promotes NUTF2 Expression Through Sponging miR-765 and Facilitates Tumorigenesis in Glioma</p>

Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer

<p>Long Non-Coding RNA NCK1-AS1 Serves an Oncogenic Role in Gastric Cancer by Regulating miR-137/NUP43 Axis</p>

Contact Info

Product

Resources

About